# Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes

> **NCT04916470** · PHASE3 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 617 (actual)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2

## Interventions

- **DRUG:** Semaglutide
- **DRUG:** Placebo (Semaglutide)

## Key facts

- **NCT ID:** NCT04916470
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-15
- **Primary completion:** 2023-10-11
- **Final completion:** 2023-10-11
- **Target enrollment:** 617 (ACTUAL)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04916470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04916470, "Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04916470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*